fiercehealthcare - The action, announced Monday, follows a comprehensive review of scientific literature by an expert panel at the agency in July, as well as a public comment period, officials said. Pharmas are expected to update and reprint their product labeling to remove…
AI Summary: Following a rigorous review of the scientific evidence, federal regulators are scrapping boxed warnings on hormone replacement products used for menopausal symptom relief. The move—aimed at increasing treatment access—casts a skeptical eye on long-held safety fears, inviting both applause and a few sarcastic raised eyebrows in the industry.
Life-extending prostate cancer drug to be offered to thousands in England / 4 months
DEA extends telehealth controlled substance flexibilities for 2026 / 4 months
AbbVie sues over Botox selection in Medicare price negotiations / 3 months
HHS drops 340B pilot following court rulings / 3 months
HHS scraps 340B rebate pilot following court rulls / 3 months
FTC settles insulin lawsuit forces Express Scripts policy changes / 3 months
Judge blocks 340B drug pricing pilot program implementation / 4 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.